Tech Company Financing Transactions
Gennao Bio Funding Round
Logos Capital, OrbiMed and Surveyor Capital invested in a $40 million Series A capital raise for Gennao Bio. This venture round was announced on 5/11/2021.
Transaction Overview
Company Name
Announced On
5/11/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to support the advancement of its proprietary, first-in-class gene monoclonal antibody platform (GMAB), exclusively licensed from Yale University, and the development of targeted nucleic acid therapeutic product candidates for the treatment of oncology and rare monogenic skeletal muscle diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
New York, NY 10001
USA
New York, NY 10001
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Squinto
Browse more venture capital transactions:
Prev: 5/11/2021: Caplight venture capital transaction
Next: 5/11/2021: Therini Bio venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs